Zdrowie i gospodarka · 29/06/2017

FDA Announces Public Comment Period for Enhanced Review Transparency Program for Biosimilar Biologics License Applications

The FDA is seeking public input on a program aimed at increasing transparency and communication for original biologics license applications submitted under the Biosimilar User Fee Act II, which could lead to user fees for review of these applications from 2018 to 2022.